Dolutegravir/lamivudine approved as dual HIV combination in EU

Simon Collins, HIV i-Base

On 3 July 2019, dolutegravir/lamivudine was approved as a two-drug fixed dose combination (FDC) in the EU. [1]

This follows approval in the US in April 2019. [2]

DTG/3TC is a once-daily combination that can be taken with or without food.

The indication is for treatment-naive adults who do not have drug resistance to either of these two drugs and approval is based on results of the phase 3 GEMINI 1 and 2 studies that were presented at the IAS conference last year. [3, 4]

The approval includes a boxed warning for management of patients coinfected with hepatitis B (HBV). All patients should be tested for HBV before starting DTG/3TC and additional treatment for HBV should be used.

There is also a caution for women to avoid dolutegravir during conception and in early pregnancy, due to a risk of neural tube defects.

Dolutegravir/3TC is manufactured by ViiV Healthcare and is marketed with the tradename Dovato.

For full details see the full product characteristics. [5]


  1. ViiV press statement. ViiV Healthcare receives EU Marketing Authorisation for Dovato (dolutegravir/lamivudine), a new once-daily, single-pill, two-drug regimen for the treatment of HIV-1 infection. (03 July 2019).
  2. FDA announcement list serve. FDA approves first two-drug complete regimen for HIV-infected patients who have never received antiretroviral treatment. (8 April 2019).
  3. Cahn P et al. Non-inferior efficacy of dolutegravir (DTG) plus lamivudine (3TC) versus DTG plus tenofovir/emtricitabine (TDF/FTC) fixed-dose combination in antiretroviral treatment-naïve adults with HIV-1 infection – 48-week results from the GEMINI studies. AIDS 2018, 23-27 July 2018, Amsterdam. Late breaker oral abstract TUAB0106LB. (abstract) (webcast)
  4. Collins S. DTG/3TC dual therapy is non-inferior to triple-ART in GEMINI study. HTB August 2018.
  5. ViiV Healthcare. US prescribing information for Dovato. (8 April 2019). (pdf)

Links to other websites are current at date of posting but not maintained.